MENU
+Compare
DNLI
Stock ticker: NASDAQ
AS OF
May 8 closing price
Price
$14.43
Change
+$0.11 (+0.77%)
Capitalization
2.08B

DNLI Denali Therapeutics Forecast, Technical & Fundamental Analysis

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease... Show more

Industry: #Biotechnology
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for DNLI with price predictions
May 08, 2025

DNLI's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for DNLI turned positive on April 09, 2025. Looking at past instances where DNLI's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for DNLI crossed bullishly above the 50-day moving average on May 01, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DNLI advanced for three days, in of 288 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 192 cases where DNLI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for DNLI moved out of overbought territory on May 01, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 58 cases where DNLI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on May 07, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on DNLI as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

DNLI moved below its 50-day moving average on May 07, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNLI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

DNLI broke above its upper Bollinger Band on April 22, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DNLI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.807) is normal, around the industry mean (14.243). P/E Ratio (0.000) is within average values for comparable stocks, (62.770). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.866). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. DNLI's P/S Ratio (3333.333) is very high in comparison to the industry average of (253.449).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNLI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

DNLI is expected to report earnings to fall 9.29% to -70 cents per share on July 31

Denali Therapeutics DNLI Stock Earnings Reports
Q2'25
Est.
$-0.71
Q1'25
Missed
by $0.08
Q4'24
Beat
by $0.17
Q3'24
Missed
by $0.03
Q2'24
Beat
by $0.08
The last earnings report on May 06 showed earnings per share of -77 cents, missing the estimate of -69 cents. With 1.32M shares outstanding, the current market capitalization sits at 2.08B.
A.I. Advisor
published General Information

General Information

a biotechnology company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
161 Oyster Point Boulevard
Phone
+1 650 866-8548
Employees
445
Web
https://www.denalitherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ABPYX11.73N/A
N/A
AB Sustainable Thematic Bal Port Advisor
VWIGX34.12N/A
N/A
Vanguard International Growth Inv
NARCX58.88N/A
N/A
Voya Multi-Manager International Sm Cp C
ONRDX23.86N/A
N/A
Invesco Rising Dividends R
MIFOX28.54N/A
N/A
Marsico Focus Institutional

DNLI and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with RCKT. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+0.77%
RCKT - DNLI
59%
Loosely correlated
+11.57%
BEAM - DNLI
55%
Loosely correlated
+6.32%
ARWR - DNLI
55%
Loosely correlated
+1.45%
ACLX - DNLI
55%
Loosely correlated
+6.27%
RGNX - DNLI
54%
Loosely correlated
-1.24%
More

Groups containing DNLI

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+0.77%
DNLI
(2 stocks)
87%
Closely correlated
+3.54%
drugs
(242 stocks)
59%
Loosely correlated
+0.99%
biotechnology
(228 stocks)
57%
Loosely correlated
+1.13%